Literature DB >> 18219319

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.

K Linke1, P D Mace, C A Smith, D L Vaux, J Silke, C L Day.   

Abstract

MDM2, a ubiquitin E3-ligase of the RING family, has a key role in regulating p53 abundance. During normal non-stress conditions p53 is targeted for degradation by MDM2. MDM2 can also target itself and MDMX for degradation. MDMX is closely related to MDM2 but the RING domain of MDMX does not possess intrinsic E3-ligase activity. Instead, MDMX regulates p53 abundance by modulating the levels and activity of MDM2. Dimerization, mediated by the conserved C-terminal RING domains of both MDM2 and MDMX, is critical to this activity. Here we report the crystal structure of the MDM2/MDMX RING domain heterodimer and map residues required for functional interaction with the E2 (UbcH5b). In both MDM2 and MDMX residues C-terminal to the RING domain have a key role in dimer formation. In addition we show that these residues are part of an extended surface that is essential for ubiquitylation in trans. This study provides a molecular basis for understanding how heterodimer formation leads to stabilization of MDM2, yet degradation of p53, and suggests novel targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18219319     DOI: 10.1038/sj.cdd.4402309

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  141 in total

Review 1.  HECT and RING finger families of E3 ubiquitin ligases at a glance.

Authors:  Meredith B Metzger; Ventzislava A Hristova; Allan M Weissman
Journal:  J Cell Sci       Date:  2012-02-01       Impact factor: 5.285

2.  Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers.

Authors:  Pavlina Dolezelova; Katerina Cetkovska; Karen H Vousden; Stjepan Uldrijan
Journal:  Cell Cycle       Date:  2012-03-01       Impact factor: 4.534

3.  Regulation of MDM2 E3 ligase activity by phosphorylation after DNA damage.

Authors:  Qian Cheng; Brittany Cross; Baozong Li; Lihong Chen; Zhenyu Li; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2011-10-10       Impact factor: 4.272

4.  Turning the RING domain protein MdmX into an active ubiquitin-protein ligase.

Authors:  Saravanakumar Iyappan; Hans-Peter Wollscheid; Alejandro Rojas-Fernandez; Andreas Marquardt; Hao-Cheng Tang; Rajesh K Singh; Martin Scheffner
Journal:  J Biol Chem       Date:  2010-08-12       Impact factor: 5.157

5.  Smad ubiquitylation regulatory factor 1/2 (Smurf1/2) promotes p53 degradation by stabilizing the E3 ligase MDM2.

Authors:  Jing Nie; Ping Xie; Lin Liu; Guichun Xing; Zhijie Chang; Yuxin Yin; Chunyan Tian; Fuchu He; Lingqiang Zhang
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

6.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

Review 7.  p53 at a glance.

Authors:  Colleen A Brady; Laura D Attardi
Journal:  J Cell Sci       Date:  2010-08-01       Impact factor: 5.285

Review 8.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

Review 9.  Structural and functional insights to ubiquitin-like protein conjugation.

Authors:  Frederick C Streich; Christopher D Lima
Journal:  Annu Rev Biophys       Date:  2014       Impact factor: 12.981

Review 10.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.